Review
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 7, 2011; 17(25): 2987-2991
Published online Jul 7, 2011. doi: 10.3748/wjg.v17.i25.2987
Table 1 Clinical characteristics and outcome of human immunodeficiency virus-negative patients with squamous cell carcinoma of the anus
AuthorTrialYrnMale (%)Age (range)Local failure (%)Overall survival
Northover et al[16]UKCCCR1987-19915774564 (26-88)3965% at 3 yr
Bartelink et al[17]EORTC1987-199410329602969% at 3 yr
Flam et al[18]RTOG 87-041987-19912913062 (29-85)24
Ajani et al[19]RTOG 98-111998-20056443155 (25-88)2584% at 3 yr
Table 2 Clinical characteristics and outcome of human immunodeficiency virus-positive patients with squamous cell carcinoma of the anus before the era of highly active antiretroviral therapy
AuthorYrnMale (%)Age (range)Toxicity 3-4 (%)Local failure (%)Overall survival
Kim et al[23]1985-1998139242806134% at 5 yr
Holland et al[24]1980-19937100411004329% at 2 yr
Peddada et al[25]1987-1995810048 (37-70)1001250% at 3 yr
Hoffman et al[26]1991-1997176425
Cleator et al[27]1989-19991210043 (30-53)502560% at 2 yr
Place et al[28]1980-19991410042 (28-58)505720% at 5 yr
Efron et al[29]1988-1999610040 (29-46)67
Table 3 Clinical characteristics and outcome of human immunodeficiency virus-positive patients with squamous cell carcinoma of the anus during the era of highly active antiretroviral therapy
AuthorYrnMale (%)Age (range)Local failure (%)Overall survival
Stadler et al[37]1998-2002810044 (34-61)5067% at 2 yr
Blazy et al[38]1997-2001910036 (35-49)11100% at 2 yr
Bower et al[39]1996-20032610042 (28-56)2347% at 5 yr
Chiao et al[40]1998-200417599.549 (43-55)66% at 4 yr
Wexler et al[41]1997-2005329445 (31-68)1665% at 5 yr
Oehler-Jänne et al[42]1997-2006409348 (34-75)6261% at 5 yr
Abramowitz et al[43]1998-200444100453285% at 3 yr
Seo et al[44]1999-2007149345 (34-59)92% at 3 yr
Barriger et al[45]1995-20081710044 (29-53)5950% at 5 yr
Hogg et al[46]1996-200621100454873% at 3 yr
Fraunholz et al[47]1997-2008219045 (31-68)4167% at 5 yr